Skip to main content

Advertisement

Table 2 Summary of adverse events

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Adverse events Total (%) Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Hemoglobin 5 (55.6) 3 (33.3) 2 (22.2) 0 0
WBC 2 (22.2) 0 2 (22.2) 0 0
Lymphopenia 3 (33.3) 2 (22.2) 0 1 (11.1) 0
Neutrophil 2 (22.2) 0 2 (22.2) 0 0
Platelet 3 (33.3) 3 (33.3) 0 0 0
Injection site reaction 9 (100) 4 (44.4) 5 (55.6) 0 0